Didanosine adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
== | ==Adverse Reactions== | ||
The following adverse reactions are discussed in greater detail in other sections: | The following adverse reactions are discussed in greater detail in other sections: | ||
Revision as of 20:21, 1 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Adverse Reactions
The following adverse reactions are discussed in greater detail in other sections:
- Pancreatitis
- Lactic acidosis/severe hepatomegaly with steatosis
- Hepatic toxicity
- Non-cirrhotic portal hypertension
- Peripheral neuropathy
- Retinal changes and optic neuritist
References
Adapted from the FDA Package Insert.